Summary
The efficacy and safety of optimally titrated once-daily (CD) and twice-daily (SR) diltiazem were compared in 111 patients with mild to moderate systemic hypertension [seated diastolic blood pressure (DBP) ≥95 mmHg and ≤114 mmHg] in a multicenter, randomized, double-blind, placebo run-in, parallel-group trial. Following a 4 week washout and placebo-controlled run-in period, patients were randomized to receive diltiazem CD 180 mg and matching placebo (n=54), or diltiazem SR 90 mg bid (n=57). Total daily doses were titrated from 180 mg to 360 mg to achieve a goal of seated DBP <90 mmHg during a 6 week titration period. The patients continued to receive their optimal dose for a 6 week follow-up period. Ninety-six (96) patients (diltiazem CD: 47, diltiazem SR: 49) completed the study protocol, with 60% of the diltiazem CD and 55% of the diltiazem SR patients achieving the goal of seated DBP of <90 mmHg (p=0.685). Although significant decreases occurred in seated and standing measurements of diastolic and systolic BP and heart rate with treatment in both groups, there were no significant differences between treatment groups. Both medications were well tolerated, with a similar frequency of adverse effects [diltiazem CD: 24/54 (37%) patients; diltiazem SR: 24/57 (42.1%) patients] with the most frequently reported adverse effects being headache and edema.
Similar content being viewed by others
References
Chaffman M, Brogden RN. Diltiazem: A review of its pharmacologic properties and therapeutic efficacy.Drugs 1985;39:387–454.
Buckley MM-T, Grant SM, Goa KL, McTavish D, Sorkin EM. Diltiazem: A reappraisal of its pharmacological properties and therapeutic use.Drugs 1990;39:757–806.
Frishman W, Kirkendall W, Lunn J, et al. Diuretics versus calcium-channel blockers in systemic hypertension: A preliminary multicenter experience with hydrochlorothiazide and sustained-release diltiazem.Am J Cardiol 1985;56:92H-96H.
Myburgh D, Gordon N. Comparison of diltiazem and atenolol in young, physically active men with essential hypertension.Am J Cardiol 1987;60:1092–1095.
Dahlöf C, Hedner T, Thulin T, Gustafsson S, Olsson S-O, for the Swedish Diltiazem-Metroprolol Multi-Centre Study Group. Effects of diltiazem and metoprolol on blood pressure, adverse symptoms and general well-being.Eur J Clin Pharmacol 1991;40:453–460.
Massie B, McCarthy P, Ramanathan K, et al. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide.Ann Intern Med 1989;107:150–157.
Torok E, Wagner M, Podmaniczky M: Comparison of diltiazem and nifedipine in hypertension.J Cardiovasc Pharmacol 1988;12(Suppl 6):S195-S196.
Simic D, Jurman V. Effects of diltiazem and nifedipine on blood pressure.J Cardiovasc Pharmacol 1988;12(Suppl 6):S220-S221.
Frohlich ED. Calcium antagonists for initial therapy of hypertension.Heart Lung 1989;18:370–376.
Pool PE, Herron JM, Rosenblatt S, et al. Metabolic effects of antihypertensive therapy with a calcium antagonist.Am J Cardiol 1988;62:109G-113G.
Schulte K-L, Meyer-Sabellek WA, Haertenberger A, et al. Antihypertensive and metabolic effects of diltiazem and nifedipine.Hypertension 1986;8:859–865.
Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. I. Diuretic drugs.Drugs 1986;32(Suppl A);260–278.
Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs.Drugs 1986;32(Suppl A);335–357.
Weinberger MH. Antihypertensive therapy and lipids: Evidence, mechanisms and implications.Arch Intern Med 1985;145:1102–1105.
Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of 6 antihypertensive agents with placebo.N Engl J Med 1993;328:914–921.
Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely MP. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice or three times daily.Clin Pharmacol Ther 1988;44:540–545.
Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Oulette VL. How often is medication taken when prescribed? A novel assessment technique.JAMA 1989;261:3272–3277.
Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patients medication compliance.Arch Intern Med 1990;150:1881–1884.
Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V).Arch Intern Med 1993;153:154–183.
Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease, part 2: Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context.Lancet 1990;335:827–838.
MacMahon S, Peto R, Cutler J, et al. Blood pressure stroke and coronary heart disease, part 1: Prolonged differences in heart disease: Prospective observational studies corrected for the regression dilution bias.Lancet 1990;335:765–774.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.JAMA 1991;265:3255–3264.
Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).Lancet 1991;338:1281–1285.
MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results.Br Med J 1992;304;405–412.
1988 Joint National Committee. The 1988 report of the Joint National Committee on detection, evaluation and treatment of high blood pressure.Arch Intern Med 1988;148:1023–1038.
Houston MC. New insights and new approaches for the treatment of essential hypertension: Selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension.Am Heart J 1989;117:911–951.
Ferdinand K, Baribian GS, Bregman H, Judelson D. The safety and efficacy of sustained-release diltiazem.Pract Cardiol 1990;16:3–11.
Frishman WH, Zawada ET, Smith LK, et al. Comparision of hydrochlorothiazide and sustained-release diltiazem for mild-to-moderate systemic hypertension.Am J Cardiol 1987;59:615–623.
Data on file. Nordic Merrell Dow.
Pool PE, Herron JM, Rosenblatt S, et al. Sustained-release diltiazem: Duration of antihypertensive effect.J Clin Pharmacol 1989;29:533–537.
Lacourcière Y, Poirier L, Boucher S, Spenard J: Comparative effects of diltiazem sustained-release and captopril on blood pressure control and plasma lipoprotein in primary hypertension: A randomized double-blind, cross-over study.J Hum Hypertens 1990;4:553–556.
Woehler TR, Eff J, Graney W, Heald D, Ziemniak J, Magner D. Multicenter evaluation of the efficacy and safety of sustained-release diltiazem hydrocholoride for the treatment of hypertension.Clin Ther 1992;14:148–157.
Massie BM, Der E, Herman TS, Topolski P, Park GD, Stewart WH. 24-hour efficacy of once-daily diltiazem in essential hypertension.Clin Cardiol 1992;15:365–368.
Felicetta JV, Serfer HM, Cutler NR, et al. A dose-response trial of once-daily diltiazem.Am Heart J 1992;123:1022–1026.
Graney WF. Clinical experience with a once-daily extended-release formulation of diltiazem in the treatment of hypertension.Am J Med 1992;93(Suppl 2A):56S-64S.
Massie B, MacCarthy EP, Ramanathan KB, et al. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide.Ann Intern Med 1987;107:150–157.
Montamat SC, Abernethy DR. Calcium antagonists in geriatric persons: Diltiazem in elderly persons with hypertension.Clin Pharmacol Ther 1989;45:682–691.
Giles TD, Massie BM: Role of calcium antagonists as imitial pharmacologic monotherapy systemic hypertension in patients over 60 years of age.Am J Cardiol 1988;61:13H-17H.
Author information
Authors and Affiliations
Consortia
Additional information
See appendix for list of participants.
Rights and permissions
About this article
Cite this article
Ruddy, T.D., Wright, J.M., Savard, D. et al. Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. Cardiovasc Drug Ther 9, 413–420 (1995). https://doi.org/10.1007/BF00879030
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00879030